Trinity Biotech’s latest clinical trial data reveals significant advancements in Continuous Glucose Monitoring (CGM) technology with its innovative CGM+ system. Unlike traditional glucose monitors, this new technology offers a multifaceted approach by tracking additional biomarkers, providing users with comprehensive health insights. This advancement addresses a significant issue faced by CGM users—reliability of readings during complex bodily changes, such as exercise or stress, by offering more than just glucose data. By going beyond glucose-only monitoring, Trinity Biotech enhances the accuracy and usability of CGM devices, promising improved health management for individuals with diabetes. Such developments are poised to transform CGM technology usage, offering users a more holistic view of their health status. The clinical trials have shown promising results, making Trinity Biotech a notable player in the medical technology field. Emphasizing accurate and broader health monitoring, this innovation marks a significant leap forward in diabetes care technology.
The Manila TimesNew data shows unclear economic impact of World Cup in Toronto
July 3, 2026
As the World Cup concludes in Toronto, questions are being raised about whether the international event delivered the anticipated economic boost. New data suggests the